Phase 1 Is Where Your Phase 3 Problems Start

We've worked in clinical research for a long time, and one of the most expensive patterns we see goes like this. Small biotech runs an ultra-lean Phase 1, gets the signal it was hoping for, and raises money on that. Then, a couple of years later, someone opens the trial master file to prepare for a pivotal study or an inspection and starts finding holes. By that point the people who could explain what happened have moved on, the sites have turned over staff, and the data is what it is.

Emerging biotechs are running on small teams and finite cash, and early-phase work can feel like something to get through quickly so the "real" program can start. But the early trials are the real program. Everything that comes later is built on top of them.

Every phase builds on the last one

Phase 1 tells you how the drug behaves in people, whether it's tolerable, and where to set the dose. Phase 2 uses that foundation to start answering whether it works. Phase 3 is designed around what the first two told you.

In oncology this chain is especially tight. Your dose escalation decisions, your DLT assessments, and your justifications for the recommended Phase 2 dose all get scrutinized again later, often by people who weren't in the room when those calls were made. If the documentation behind those decisions is thin, you'll end up defending them from memory.

In rare disease it's even less forgiving: when you only have a handful of patients, every one of them carries a lot of evidentiary weight, and you rarely get a second chance to enroll them.

What underinvesting actually costs

Lean operations are a strength. Most small biotechs we work with are faster and more decisive than big pharma, and that's a big part of why they can do what they do. The trap is treating clinical quality as one of the places to save money.

Problems like protocol deviations, uneven monitoring, and incomplete records tend to stay hidden until the worst possible moment, usually Phase 3 planning, a partnering due diligence, or audit prep. And the fixes at that stage are ugly:

• Data that was never collected from those early phase patients can't be collected from them now.

• Gaps in the documentation become questions from regulators, and questions cost time. Time is money!

• Results that are ambiguous because of how the study was run, not because of the drug, can push you into repeating work you thought was finished.

None of this is about perfection. It's about generating data you'd be comfortable defending in front of a regulator, an investor, or a potential partner.

Building quality by design, without the bureaucracy

The current version of ICH GCP (E6(R3)) leans hard on a principle that good operators have followed for years: figure out what actually matters to your trial before the first patient enrolls, and focus your effort there. Usually that means your critical endpoints, your safety data, and the handful of processes that protect them.

That's good news for small teams. Risk-proportionate quality doesn't mean more SOPs and more approval layers. It means putting experienced people on the parts of the study that matter most, and not drowning everyone in paperwork on the parts that are less critical.

Software helps. It doesn't replace judgment.

We like good software, and we use plenty of it. But a dashboard has never picked up the phone, talked a struggling site coordinator through a confusing section of the protocol, or quietly figured out that the real problem was the site's staffing.

That kind of judgment comes from people who have done the work many times:

• A field CRA who has managed dozens of sites can tell the difference between a one-off mistake and a site that fundamentally misunderstands the protocol.

• A good QA lead spots the data integrity issue while it's still a small fix, not a finding.

• An experienced regulatory specialist knows which early protocol decisions will come back up in a marketing application, and which won't matter.

With novel modalities, small patient populations, and unusual endpoints, there's often no playbook to follow. That's exactly when experience earns every penny.

Practical Support for Lean Biotechs

We started OWL in 2010 because we thought sponsors deserved access to senior people without having to buy an entire full-service org chart to get them. That's still how we work.

OWL provides direct access to senior CRAs, quality assurance managers, and regulatory advisors who integrate directly into your existing team. Our flexible support model delivers targeted expertise without the heavy overhead or rigid structures of traditional full-service CROs.

We help sponsors safeguard their asset value from the very first patient, ensuring early data withstands regulatory and commercial scrutiny down the road.